Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID -- Ignore unavailable to you. Want to Upgrade?

To: Roudy who wrote (1416)	1/13/1998 1:54:00 AM
From: Maurice Winn	Read Replies (1) \| Respond to of 1762

Don, just a little bit of info, but a doctor here in the haematology department of Auckland Hospital claims not to think much of Rituxan, preferring I131 treatment prospects. New Zealand will be a while yet approving Rituxan. Maybe 6 months. It remains a puzzle to me as to why the FDA only approves it for follicular low grade lymphomas when anything with a CD20 hanging around should be approved. With the minimal side effects compared with the shambles that cyclophosphamide, vincristine and adriamycin cause in a person it seems crazy not to use it anywhere CD20 cells are being targeted as an adjunct therapy. Safety was established in other trials. Efficacy seems obvious. What is being achieved by making a rigmarole of approvals for other CD20 antigen lymphomas? It beats me why New Zealand should add six months to approvals. Smells like bureaucracy. Maybe marketing slackness by the companies who are supposed to promote it here. Bloody hopeless in my opinion. Meanwhile, people who could be helped will suffer and die, the beneficiaries of their wills will blow the money on gin instead of treatment, the companies who produce and sell the product forego income. Maurice